Please assess the completion status of the following clinical trial:

Trial Title: AZD0585 Phase III Long-term Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Japanese men or women, ≥20 years of age.~* Subjects must meet all of the following criteria;~  1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 - 499 mg/dL~ 2. %TG change between Visit 2 and Visit 3 must be within 30%~ 3. %LDL-C change between Visit 2 and Visit 3 must be within 25%~Key Exclusion Criteria:~* Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.~* Known lipoprotein lipase impairment or deficiency, or Apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.~* Current or history of pancreatitis.~* Type I diabetes mellitus, use of insulin, or haemoglobin A1c \>10% at Visit 1.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- AZD0585 2g group (Type: EXPERIMENTAL): AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
- AZD0585 4g group (Type: EXPERIMENTAL): AZD0585 1g × 4 capsules once daily
- Placebo control group (Type: PLACEBO_COMPARATOR): AZD0585 placebo 1g × 4 capsules once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).